Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Sarcoma × fluoroazomycin arabinoside × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hypoxia 4 Uterine Cervical Neoplasms 3 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Hypoxic Tumours 1 Head and Neck Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Adenosquamous 1 Adenocarcinoma 1

Interventions

Doxorubicin 60 Radiotherapy 45 Ifosfamide 42 Gemcitabine 38 Cyclophosphamide 30 pazopanib 27 Docetaxel 25 pembrolizumab 23 Nivolumab 22 Filgrastim 22 Trabectedin 19 Etoposide 19 Surgical Procedures, Operative 18 Cisplatin 18 Blood Specimen Collection 16 Radiation 13 Carboplatin 13 Magnetic Resonance Spectroscopy 12 Ipilimumab 12 liposomal doxorubicin 11 Vincristine 11 Bevacizumab 11 apatinib 10 anlotinib 10 Temozolomide 10 Radiosurgery 10 Peripheral Blood Stem Cell Transplantation 10 Melphalan 10 Drug Therapy 10 Sorafenib 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03418818 2026-03-06

FAZA PET/MRI Sarcoma

University Health Network, Toronto

Phase NA Active not recruiting

Hypoxia, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡